Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 8/20 | 0.87 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.87 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | TDP2 | O95551 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10004303 | 0.98 | PNMT (0.84) | PNMTADRA2AASIC3ADRA2BADRA2C | |
| SCHEMBL324460 | 0.93 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL29382023 | 0.93 | PNMT (1.00) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL29651180 | 0.92 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL325622 | 0.92 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL27698594 | 0.92 | PNMT (0.97) | PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL717840 | 0.89 | PNMT (0.81) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| 1,2,3,4-Tetrahydroisoquinoline SCHEMBL5485986 | 0.89 | PNMT (0.85) | PNMTADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL1947220 | 0.88 | PNMT (0.78) | PNMTADRA2AADRA2BADRA2CTDP2 | |
| SCHEMBL383577 | 0.85 | PNMT (0.74) | PNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241559-A | Quinazoline macrocyclic compound serving as HPK1 kinase inhibitor and preparation method and application thereof | 深圳市新樾生物科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4464699-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | Lisen Therapeutics, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240360145-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | LISEN THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| CN-109810111-B | Pyrazolopyrimidine compound, and preparation method and application thereof | 上海医药集团股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023134582-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海立森印迹医药技术有限公司 | 2023-07-20 | — | — | WO | disclosed |
| CN-116444488-A | Pyrimidine-2, 4-diamine derivative and preparation method and application thereof | 上海立森印迹医药技术有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-11427542-B2 | Compounds for treatment of cardiac arrhythmias and heart failure | ELEX BIOTECH, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-0832069-B1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-1181954-A2 | Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion | PFIZER INC. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| US-6121283-A | Apo B-secretion/MTP inhibitory amides | PFIZER INC (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0944602-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5919795-A | ATHEROSCLEROSIS THERAPY | PFIZER INC. (US) | 1999-07-06 | — | — | US | disclosed |
| WO-1998023593-A1 | APO B-SECRETION/MTP INHIBITORY AMIDES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| EP-0832069-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040640-A1 | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360145-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | DPYD, TYMP, TYMS | PNMT 1192/4885ADRA2A 2491/4885ASIC3 3988/4885 |
| US-20240228459-A1 | WEE1 INHIBITORS AND USES THEREOF | WEE1, WEE2, DCLRE1B | PNMT 2907/4885ADRA2A 4765/4885ASIC3 4318/4885 |
| US-11427542-B2 | Compounds for treatment of cardiac arrhythmias and heart failure | RYR2, RYR1, CACNA1F | PNMT 3907/4885ADRA2A 256/4885ASIC3 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.